Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs
LUND, Sweden, Jan. 31, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, today announces the appointment of Norma Alonzo Palma, PhD as Vice President of Clinical and Medical Affairs.
- LUND, Sweden, Jan. 31, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, today announces the appointment of Norma Alonzo Palma, PhD as Vice President of Clinical and Medical Affairs.
- As announced in July 2023, Immunovia significantly restructured to focus its resources on the company's next-generation blood test for early detection of pancreatic cancer.
- Norma most recently held the position of VP of Medical Affairs at Aadi Biosciences where she developed and executed the medical strategy and plan.
- She will also strengthen Immunovia's partnerships with key opinion leaders, leading clinicians, and payers," says Jeff Borcherding, CEO and President of Immunovia.